2013 – First POC for wound healing

UCB-MNC-derived EV are shown to accelerate wound healing in vivo, in healthy and diabetic animals

2014 – UCB-MNC-EV demonstrated to be superior to platelet-derived growth factor BB.

Possible mechanism of action uncovered.

Read publication

2014 – Exogenus’ founders participate in a technology commercialization acceleration program

2015 – Provisional patent submitted to USPTO

2015 – Exogenus Therapeutics was founded by Joana Correia, Luísa Marques and Ricardo Neves, as a result of winning COHiTEC.

2015 – Newly-founded Exogenus Therapeutics secured €100K in pre-seed investment

2015 – Exclusive licensing of patent WO/2017/163132 to Exogenus Therapeutics

Link to patent

2015 – Exogenus Therapeutics is awarded ANJE‘s Young Entrepreneur Award

2015 – Exogenus Therapeutics secures €800K in seed funding.

2016 – Development of an optimized, GMP-compliant and scalable method for the production of umbilical cord-blood derived EV (Exo-101)

Read publication

2016 – Exogenus Therapeutics is selected to receive support from Horizon 2020’s SME Instrument Phase 1

2016 – Exogenus Therapeutics awarded with the Everis Foundation award

2017 – Joana Correia, Exogenus Therapeutic’s founder, CEO and CSO, recognized as a Young Transatlantic Innovation Leader

2017 – Exogenus Therapeutics selected as one of the most innovative Life Sciences & Medtech projects in Europe at Merck Venture Lounge

2017 – Exogenus Therapeutics recognized at BioEurope, in Berlin

2018 – Development of a poloxamer-based hydrogel for Exo-101 delivery in wounds

2018 – Filing of international patent PCT/IB2019/058462: Compositions Comprising Small Extracellular Vesicles Derived From Umbilical Cord Blood Mononuclear Cells With Anti-Inflammatory And Immunomodulatory Propertiess

2018 – Exogenus Therapeutics is selected as one of the top 500 Deep Tech Startups of Hello Tomorrow

2019 – Exogenus Therapeutics awarded the Prémio Empreendedor XXI 2018

2019 – Exogenus Therapeutics secures funding under Horizon 2020 INNOSUP

2020 – Exogenus Therapeutics selected to participate in Novartis SciCare Accelerator Program

2020 – Exogenus Therapeutics wins grant to study umbilical cord blood exosomes for the treatment of lung inflammation

2021 – Exogenus’ platform for EV isolation and characterization published in Stem Cells Translational Medicine

021 – Patent rights granted in Japan

2021 –Publication of non-GLP study results concerning Exo-101’s safety and biodistribution in rats

2021 – Publication of Exo-101’s effect in inflammation and skin diseases

2021 – Exogenus awarded at the Go Global Awards

2022 – Exogenus and Boehringer Ingelheim announce joint project to study Exo-101 in regenerative medicine indications

2022 – Patent rights granted in China and Korea

2022 – Patent submission concerning the use of Exo-101 in fibrotic disorders

2022 – Exogenus wins at the 5th edition of Blue Bio Value Accelerator, with a circular economy project focused on microalgae extracellular vesicles

2022 – Collaborative R&D project for gene delivery using EV-associated AAV

2023 – Collaborative R&D project with global pharmaceutical company to explore drug’s MoA

2023 – Patent rights granted in Canada 

2024 – Exogenus secures funding by 3XP Global to accelerate pipeline development 

2024 – Exogenus patent granted in Japan